Company Overview - Agilent Technologies, Inc. is based in Santa Clara, California, and provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets, with a market cap of $33 billion [1]. Market Position - Agilent is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size, influence, and dominance in the diagnostics and research industry [2]. Stock Performance - The company's shares have declined 28.3% from their 52-week high of $160.27, reached on November 25, 2025, and have fallen 20% over the past three months, underperforming the S&P 500 Index's 1.5% drop during the same period [3]. - Year-to-date, Agilent's shares are down 15.6%, while the S&P 500 has seen a marginal decline. Over the past 52 weeks, Agilent has fallen 5.8%, trailing behind the S&P 500's 20.9% increase [5]. Trading Trends - Agilent has been trading below its 200-day moving average since early February and below its 50-day moving average since mid-January, confirming a bearish trend [5]. Financial Results - In Q1, Agilent reported net revenue of $1.8 billion, a 7% year-over-year increase, meeting consensus estimates. However, its adjusted EPS of $1.36 rose 3.8% from the previous year but missed analyst expectations by a penny, leading to a 3% drop in shares following the results [7]. Competitive Analysis - Agilent has underperformed its rival, Thermo Fisher Scientific Inc., which declined 5.4% over the past 52 weeks and 14% year-to-date [8]. Analyst Sentiment - Despite recent underperformance, analysts maintain a "Strong Buy" consensus rating for Agilent, with a mean price target of $165.47, indicating a potential 42.5% premium to current price levels [8].